Trial Profile
Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Brigatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ALTA-2
- Sponsors ARIAD Pharmaceuticals; Takeda; Takeda Pharma
- 10 Aug 2023 Planned End Date changed from 30 Jun 2023 to 28 Jun 2024.
- 15 Nov 2022 Planned End Date changed from 30 Oct 2022 to 30 Jun 2023.
- 13 Sep 2022 Results of pooled analysis from NCT03535740 and NCT03410108 of exploratory integrated analysis of the impact of EML4-ALK fusion and secondary ALK mutations on efficacy with brigatinib in alectinib-refractory ALK+ NSCLC patients, presented at the 47th European Society for Medical Oncology Congress